Healing & recoveryAnti-aging & longevity
Thymosin alpha-1
Tα1 · Thymalfasin · Zadaxin (brand)
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus, the organ that trains T cells. It is genuinely a medicine in much of the world: approved in over thirty countries as thymalfasin, principally for chronic hepatitis B, and used in some settings for sepsis and as a vaccine adjuvant.
It is not approved in the United States, which puts it in an unusual position: a compound with substantial clinical use and published trials, sold domestically as a research chemical because the approval happens to be somewhere else.
Unlike TB-500, which is a fragment of a different thymic protein and has no human data, thymosin alpha-1 is the full peptide with real clinical evidence behind it. The names are similar enough that they get conflated constantly, and they are not comparable in evidence.
How it works
Thymosin alpha-1 acts on Toll-like receptors on dendritic cells and influences T cell maturation, pushing the immune response toward a Th1 pattern, the arm that deals with intracellular pathogens and abnormal cells.
It is an immune modulator rather than an immune stimulant, which is a meaningful distinction: the reported effect is on how the response is shaped rather than simply how strong it is. That is also why the caution around autoimmune disease is a genuine one rather than boilerplate.
Regulatory status — United States
Approved as thymalfasin in more than thirty countries, principally for chronic hepatitis B. Not approved in the United States, where it is sold as a research chemical with no manufacturing standard behind it.
Last reviewed 12 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.
What it is studied for
Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.
Chronic hepatitis B
Clinical trialThe main approved indication.
EvidenceClinical trials supporting approval in over thirty countries.
Sepsis
Clinical trialStudied as an adjunct in severe infection.
EvidenceRandomised trials with mixed results. An area of ongoing study, not a settled use.
General immune support
Community practiceThe reason it is used in this community.
EvidenceNot studied as an endpoint in healthy adults. Extrapolated from use in disease states.
Identity and clearance
Molecule
- Class
- Thymic peptide, immune modulator
- Molecular weight
- 3108.3 Da
- Length
- 28 amino acids
The full naturally occurring peptide, not a fragment. That is what distinguishes it from TB-500.
Pharmacokinetics
Clinical trialShort-acting. That is why approved regimens use twice-weekly subcutaneous dosing over months.
Dose protocols reported in sources
Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.
| Goal | Dose | Frequency | Route | Units, 5 mg vial | Source | Start this protocol |
|---|---|---|---|---|---|---|
| Approved regimen for hepatitis B | 1.6 mg | Twice weekly for six months | Subcutaneous | 64 u | Clinical trial | Start this |
| Commonly described for general use | 450 mcg – 1.6 mg | Two or three times weekly | SubcutaneousBelow the approved regimen, and for an indication that has not been studied. | 18–64 u | Community practice | Start this |
Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.
CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.
Calculator
Work out what to draw
Pre-filled with a 10 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.
Draw to 32 units on a 1 mL U-100 syringe. That is 0.32 mL, containing 1.6 mg of Thymosin alpha-1.
32 units sits exactly on a printed line.
Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.
Open this calculation in the full calculator
Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.
Safety
Reported effects
- Injection site redness or discomfortClinical trial
Common in trials
The most frequently reported effect, and generally mild.
- Transient fatigueCommunity practice
Occasionally reported
- Generally well toleratedClinical trial
Documented across trials
Its tolerability in clinical use is one of the better-established things about it.
When to stop
- Any new joint pain, rash, or unexplained fever. These can be early signs of immune activation going the wrong way.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- A flare of any existing autoimmune condition.
- Signs of infection at an injection site.
Interactions and situations that need care
- Autoimmune diseaseAvoid
This modulates T cell responses toward a more active pattern. In a condition where the immune system already attacks the body's own tissue, pushing that direction is the specific thing you would not want, and it has not been studied.
- Immunosuppressant therapy or transplantAvoid
Immunosuppression after a transplant exists to prevent rejection. An immune modulator works directly against that, and the consequence of getting it wrong is organ loss.
- Pregnancy and breastfeedingAvoid
No reproductive or developmental safety data.
What to expect
- The clinical evidence concerns hepatitis B and sepsis, in people with those conditions. General immune support in healthy adults is not what was studied.
- Approved regimens run for months, not weeks. In its evidenced use this is not a short course.
- Its tolerability is well established, which is genuinely unusual for anything on this site.
- Material sold in the United States is not the approved product, so the trial evidence does not follow it.
Storage and handling
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
With other peptides
- Thymalincaution
Thymalin is an undefined calf thymus extract, and thymosin alpha-1 was originally identified as a component of exactly that kind of preparation. Running both is probably taking the same thing twice, once in a known quantity and once in an unknown one.
- Thymulincaution
Both are thymic peptides acting on T-cell function. Thymosin alpha-1 has registered clinical use in several countries and thymulin has none, so running both adds an unstudied compound to a studied one for overlapping effect.
Checking your vial
Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.
White cake, clear solution
Standard for a peptide of this size.
Collapsed cake or cloudy solution
Indicates heat damage or degradation.
Questions
- Is thymosin alpha-1 the same as TB-500?
- No, and the confusion is common. Thymosin alpha-1 is a full 28-amino-acid peptide with clinical trials and approvals in over thirty countries. TB-500 is a fragment of thymosin beta-4 — a different protein — and it has no completed human trials. Similar names, entirely different evidence.
- Why is it not approved in the United States?
- It holds approvals in more than thirty countries but has not completed the US regulatory pathway for its indications. That is a regulatory fact rather than a safety finding.
References
Thymosin alpha-1: from bench to bedside, clinical development and use
Annals of the New York Academy of Sciences / review literature, 2012 · Review of clinical trials and approved use
Humans
Reviews approval for chronic hepatitis B across multiple jurisdictions, trial evidence in sepsis and as a vaccine adjuvant, and a consistently favourable tolerability profile.
Commonly reported community protocols
Bioalmanac editorial summary of public community sources, 2026 · Not a study
Summarises dose ranges described for general immune use, an indication with no supporting trials. Carries no evidential weight.
Related compounds
Thymalin
A thymus extract used as a medicine in Russia for decades. Not a single defined peptide, which is the fact that governs everything else on this page.
Thymulin
A genuine thymic hormone with real immunology behind it, and no clinical development. It only works with zinc bound to it, which is the most useful fact about it.
BPC-157
A synthetic 15-amino-acid peptide studied in animals for effects on tendon, ligament and gut tissue repair. No completed human trials.
TB-500
A synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. Animal evidence only.
Next
What to do with Thymosin alpha-1
- Keep a record of itTurn a dose and a schedule into a protocol, then log what you actually take. Thymosin alpha-1 is filled in for you.
- See what it costsPer-milligram prices read from vendor sites and confirmed by a person, so vial sizes compare.
- Check a combinationWhat our profiles record about Thymosin alpha-1 alongside each other compound — including the pairs where nothing is recorded.
Keep this page honest
If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.
Page last updated 12 Aug 2026